Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer
29 Novembre 2022 - 1:00PM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for cancer, today announced the appointment of Nancy
Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory
Officer. Dr. Boman will spearhead Adicet’s regulatory strategy to
further advance existing and new pipeline opportunities for the
Company’s gamma delta T cell platform.
“We are incredibly excited to welcome Nancy to the Adicet team,”
said Chen Schor, President and Chief Executive Officer of Adicet
Bio. “Her vast experience in successfully filing marketing
applications for more than 15 products, including in hematologic
malignancies, such as non-Hodgkin’s lymphoma, is perfectly aligned
with our plan to initiate a potentially pivotal program for ADI-001
in the first half of 2023. Nancy’s leadership in building and
expanding global regulatory operations particularly in the oncology
field, including in solid tumors, is an asset to the team and
positions us well as we expect to submit an IND application for
ADI-925 in the second half of 2023 and potentially advance other
pipeline programs, as disclosed in our recent R&D event, to
regulatory submissions and clinical trials.”
“I am pleased to join the Adicet team during this pivotal time
in the Company’s growth trajectory,” commented Dr. Boman, Senior
Vice President and Chief Regulatory Officer of Adicet Bio. “With
the positive updates on ADI-001 to date and an emerging preclinical
pipeline of potentially best-in-class gamma delta T cell therapy
product candidates, I look forward to supporting the team in
bringing novel therapies to patients in need.”
Dr. Boman has nearly 30 years of industry experience in the
biotech and pharmaceutical industry with expertise in clinical
development, chemistry, manufacturing and controls management, and
regulatory operations leading more than 15 drug marketing
applications. She joins Adicet from Encoded Therapeutics, Inc.,
where, as a Chief Regulatory Officer, she built and oversaw all
aspects of the regulatory department for its gene therapy
candidates. Previously, Dr. Boman led the regulatory affairs
practice as Chief Regulatory Officer at AveXis Inc. (now Novartis
Gene Therapies), helping manage product candidate Zolgensma®, as
well as expand the commercialization of adeno-associated
virus-based innovative gene therapies. Prior to that she served as
Senior Vice President, Regulatory Affairs and Pharmacovigilance at
Alder BioPharmaceuticals, Inc., and has also held positions in
regulatory affairs and clinical development at Cell Therapeutics,
Inc., Genentech, Inc. and Amgen, Inc. Dr. Boman received her M.D.
in Human Medicine, her Ph.D. in Biochemistry, and B.Sc. in General
Science from The University of British Columbia.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with chimeric antigen receptors (CARs)
and adaptors (CAds), to enhance selective tumor targeting and
facilitate innate and adaptive anti-tumor immune response for
durable activity in patients. For more information, please visit
our website at https://www.adicetbio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" of
Adicet within the meaning of the Private Securities Litigation
Reform Act of 1995 relating to business and operations of Adicet.
These forward-looking statements include, but are not limited to,
express or implied statements regarding future plans and
expectations for ADI-001 and Adicet’s preclinical programs; the
anticipated timing for the initiation of a potentially pivotal
study for ADI-001 and investigational new drug (IND) application
for ADI-925; Adicet’s expected growth as a company; and the
anticipated contribution of the members of Adicet’s executive team
to the Company’s operations and progress.
Any forward-looking statements in this press release are based
on management's current expectations and beliefs of future events,
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements,
including without limitation, the effect of COVID-19 on Adicet’s
business and financial results, including with respect to
disruptions to Adicet’s business operations and ability to raise
additional capital; Adicet's ability to execute on its strategy,
including obtaining the requisite regulatory approvals on the
expected timeline, if at all; that positive results from
preclinical studies may not necessarily be predictive of the
results of any future clinical studies; any future preclinical or
clinical studies may fail to demonstrate adequate safety and
efficacy of Adicet’s product candidates, which would prevent,
delay, or limit the scope of regulatory approval and
commercialization; and regulatory approval processes of the U.S.
Food and Drug Administration and comparable foreign regulatory
authorities are lengthy, time-consuming, and inherently
unpredictable. For a discussion of these and other risks and
uncertainties, and other important factors, any of which could
cause Adicet's actual results to differ from those contained in the
forward-looking statements, see the section titled "Risk Factors"
in Adicet's most recent Annual Report on Form 10-K for the year
ended December 31, 2021 and subsequent filings with the SEC. All
information in this press release is as of the date of the release,
and Adicet undertakes no duty to update this information unless
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221129005329/en/
Adicet Bio., Inc. Investor and Media Contacts
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Lug 2023 a Lug 2024